GSK closing Stiefel plants
This article was originally published in The Tan Sheet
GlaxoSmithKline will close the Oak Hill, N.Y., and Sligo, Ireland manufacturing facilities of recently acquired Stiefel Laboratories by the end of 2012, a Stiefel spokeswoman said in a Nov. 13 e-mail. Production will continue at the sites until the products are transferred to other facilities, including contract manufacturers. Stiefel said 263 employees work at the Oak Hill plant and 250 at the Sligo site. When GSK acquired Stiefel for $2.9 billion in cash in April, it said it expected to more than double its dermatology sales to $1.5 billion by creating a global specialist business across Rx and OTC products (1"The Tan Sheet" April 27, 2009)
You may also be interested in...
GlaxoSmithKline will more than double its dermatology sales to $1.5 billion by acquiring Stiefel Laboratories and creating a global specialist business across Rx and OTC drugs
Business development leaders and venture capital investors spoke at Biocom’s annual partnering conference about what they are seeking in relationships with entrepreneurs and start-ups.
Mylan’s full year 2019 earnings report was its last as an independent company, so the focus was on the coming merger with Pfizer’s Upjohn and growth prospects for the new company, Viatris.